Court Denies Renovaro Motion for an Expedited Trial in July
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Court Denies Renovaro Motion for an Expedited Trial in July
May 27, 2025 8:35 AM EDTPITTSBURGH, May 27, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today issued the following statement regarding its dispute with Renovaro, Inc.
Contrary to a press release issued by RENB, the Delaware Court of Chancery recently rejected RENBs request for an expedited, two-day trial in July. The Court reached this decision citing RENBs delay in bringing its action.Â
POAI fully intends to protect its rights and defend against the claims asserted by RENB that are premised on inaccurate allegations and lack any merit. The... More
